CORDIS
EU research results

CORDIS

English EN
Testing the value of a novel strategic approach and its cost efficacy to improve the poor outcomes in Cardiogenic Shock

Testing the value of a novel strategic approach and its cost efficacy to improve the poor outcomes in Cardiogenic Shock

Objective

Heart attacks are common and can leave survivors suffering cardiogenic shock (CGS), with its extremely high risk of early death (42% versus 4% for non-CGS) and high incidence of chronic heart failure, with its associated socio-economic disease burden (ill-health, recurrent heart failure admissions, no return to full time activities, need for expensive therapeutic devices and life-long drugs). Outcomes from CGS are even worse in, females, the elderly (mortality>70%) and high risk sub-groups. The incidence of CGS in Europe alone is >50 000 patients pa. This unacceptably high mortality/morbidity rate represents a true unmet clinical need. No clear strategy exists to improve outcomes, with ad hoc therapies given too late in a spiralling, irrecoverable process.
EURO SHOCK aims to improve outcomes for CGS patients. At its core is a robust phase3 randomised trial comparing a novel strategy of very early use of ECMO (Extracorporeal Membrane Oxygenation) to current standard of care. Evidence suggests very early ECMO will halt the spiral of decline and so significantly reduce 12 month death rate and need for heart failure re-admissions. Since both costs of CGS, and ECMO are high a health-economic cost efficacy analysis will be core. A cardiac magnetic resonance imaging sub-study will test novel protocols in sick patients and provide mechanistic data. We will test transfer networks for CGS patients and analyse ECG data to determine which patients benefit most from early transfer.
Our multidisciplinary consortium comprises renowned physician-scientists, statisticians, health economists and technology providers, including specialised ECMO SME.
EURO SHOCK will impact on heart attack survivors, healthcare providers and Europe`s medical technology sector by 1) reducing healthcare costs associated with CGS 2) provide novel cost effective framework for cardiac interventions 3) delivering innovative healthcare technologies and 4) informing guidelines for effective CGS intervention.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITY OF LEICESTER

Address

University Road
Le1 7rh Leicester

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 266 312,50

Participants (13)

Sort alphabetically

Sort by EU Contribution

Expand all

DEUTSCHES HERZZENTRUM MUNCHEN

Germany

EU Contribution

€ 252 500

UNIVERSITY OF GLASGOW

United Kingdom

EU Contribution

€ 1 327 843,50

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

EU Contribution

€ 517 400

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN

Germany

EU Contribution

€ 252 500

CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER

Spain

EU Contribution

€ 360 812,50

UNIVERSITETET I TROMSOE - NORGES ARKTISKE UNIVERSITET

Norway

EU Contribution

€ 303 750

PAULA STRADINA KLINISKA UNIVERSITATES SLIMNICA

Latvia

EU Contribution

€ 82 500

AZIENDA OSPEDALIERA PAPA GIOVANNI XXIII

Italy

EU Contribution

€ 252 375

UNIVERSITAIR ZIEKENHUIS ANTWERPEN

Belgium

EU Contribution

€ 252 500

UNIVERSITY OF EAST ANGLIA

United Kingdom

EU Contribution

€ 267 717,50

UNIVERSITAT POLITECNICA DE CATALUNYA

Spain

EU Contribution

€ 148 440

CHALICE MEDICAL LIMITED

United Kingdom

EU Contribution

€ 793 750

ACCELOPMENT AG

Switzerland

EU Contribution

€ 421 171,88

Project information

Grant agreement ID: 754946

Status

Ongoing project

  • Start date

    1 January 2018

  • End date

    31 December 2022

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 6 499 572,88

  • EU contribution

    € 6 499 572,88

Coordinated by:

UNIVERSITY OF LEICESTER

United Kingdom